Metastasis in neuroblastoma: the MYCN question
Frontiers in Oncology · 18.05.2023 · 13
DOI: 10.3389/fonc.2023.1196861 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Oncology, online erschienen am 18.05.2023. Verfasst von Swapnil Parashram Bhavsar. Beteiligte Einrichtung: Pediatric Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Barnekreftforeningen.
Abstract (Originalsprache)
Oncogenic drivers like MYCN in neuroblastoma subsets continues to present a significant challenge owing to its strong correlation with high-risk metastatic disease and poor prognosis. However, only a limited number of MYCN-regulatory proteins associated with tumor initiation and progression have been elucidated. In this minireview, I summarize the recent progress in understanding the functional role of MYCN and its regulatory partners in neuroblastoma metastasis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Research Group, Department of Clinical Medicine, Faculty of Health Sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
Förderung
- Barnekreftforeningen
Zitieren
APA
Bhavsar, S. P. (2023). Metastasis in neuroblastoma: the MYCN question. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1196861
Vancouver
Bhavsar SP. Metastasis in neuroblastoma: the MYCN question. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1196861
BibTeX
@article{Bhavsar2023,
author = {Bhavsar, Swapnil Parashram},
title = {Metastasis in neuroblastoma: the MYCN question},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1196861}
}
EUVIMED